ROCKVILLE, Maryland, March 24, 2017
Emflaza is the first treatment approved in the U.S. for DMD patients 5 years and older, regardless of genetic mutation
Aligns with PTC's mission and commitment to the DMD community
$140 million upfront consideration (comprised of cash and PTC common stock) plus potential contingent payments based on net sales and single milestone payment
PTC to host investor conference call today, March 16, 2017 at 8:30 am ET
Investment will support development of ALS drug “enhancer”
New investment builds on recent breakthroughs with availability of three new neuromuscular disease drugs
The Muscular Dystrophy Association (MDA) is a qualified 501(c)(3) tax-exempt organization.
©2018, Muscular Dystrophy Association Inc. All rights reserved.